This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neurology	Sirtuin 1 (SIRT1)	<i>In vitro</i> and mouse studies suggest inhibiting SIRT1 could help treat myelination disorders. In a mouse model for lysolecithin-induced demyelination, genetic inactivation of <i>Sirt1</i> increased remyelination compared with <i>Sirt1</i> activation. In a mouse model for experimental autoimmune encephalomyelitis (EAE), <i>Sirt1</i> inactivation delayed paralysis. Next steps include testing pharmacological inhibitors of SIRT1 in animals. Elixir Pharmaceuticals Inc. and Siena Biotech S.p.A. have the SIRT1 inhibitor EX-527 in Phase I testing to treat Huntington's disease (HD). SciBX 6(21); doi:10.1038/scibx.2013.525 Published online May 30, 2013	Findings unpatented; licensing status not applicable	Rafalski, V.A. <i>et al. Nat. Cell Biol.</i>; published online May 5, 2013; doi:10.1038/ncb2735 Contact: Anne Brunet, Stanford University School of Medicine, Stanford, Calif. e-mail: anne.brunet@stanford.edu